Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02851849 · ClinicalTrials.gov registry record · Phase 2

A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

A Phase 2 study of Type 2 Diabetes Mellitus, sponsored by Ligand Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
148
Enrollment target
20
Study locations

NCT02851849 is a Phase 2 study of Type 2 Diabetes Mellitus that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 148 participants, below the 2,747-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02851849, a Phase 2 study of Type 2 Diabetes Mellitus, has completed, sponsored by Ligand Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
148 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c) during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects with Type 2 Diabetes Mellitus (T2DM)

Conditions Studied

Type 2 Diabetes Mellitus

Interventions

  • OTHER Placebo
  • DRUG LGD-6972-5 mg
  • DRUG LGD-6972-10 mg
  • DRUG LGD-6972-15 mg

Study Locations (20)

California

  • - Huntington Park
  • - Los Angeles
  • - Montclair
  • - North Hollywood
  • - San Diego

Florida

  • - Brooksville
  • - Miami
  • - Orlando
  • - Tampa

Arizona

  • - Chandler
  • - Surprise

North Carolina

  • - Durham
  • - Greensboro

Alabama

  • - Tuscumbia

Colorado

  • - Denver

Illinois

  • - Chicago

Nevada

  • - Las Vegas

Trial Details

FieldValue
Enrollment Target 148 participants
Start Date 2016-09
Est. Completion 2017-06
Phase Phase 2

Sponsor

Ligand Pharmaceuticals

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02851849

The ClinicalTrials.gov registry entry for NCT02851849 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,747-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (95% lower). The listed sponsor is Ligand Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT02851849 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT02851849 about?

NCT02851849 is a clinical study titled "A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c) during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects with Type 2 Diabetes Mellitus (T2DM)

What is the current status of trial NCT02851849?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2016-09. Estimated completion is 2017-06.

What conditions does trial NCT02851849 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT02851849?

The interventions under investigation include: Placebo (OTHER), LGD-6972-5 mg (DRUG), LGD-6972-10 mg (DRUG), LGD-6972-15 mg (DRUG).

Who is sponsoring clinical trial NCT02851849?

This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02851849 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes Mellitus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.